高级检索
中华神经科杂志
期刊首页
过刊列表
高级检索
稿件发表
• 指南 •
ENGLISH ABSTRACT
中国帕金森病治疗指南（第四版）
中华医学会神经病学分会帕金森病及运动障碍学组
中国医师协会神经内科医师分会帕金森病及运动障碍学组
作者及单位信息
·
DOI： 10.3760/cma.j.cn113694-20200331-00233
Chinese guidelines for theTreatment of Parkinson′s disease (fourth edition)
Chinese Society of Parkinson′s Disease and Movement Disorders
Parkinson′s Disease and Movement Disorder Section of Neurologist Branch of Chinese Medical Doctor Association
Chen Shengdi
Chen Haibo
Authors Info & Affiliations
Chinese Society of Parkinson′s Disease and Movement Disorders
Parkinson′s Disease and Movement Disorder Section of Neurologist Branch of Chinese Medical Doctor Association
Chen Shengdi
Department of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Treatment and Research Center of Parkinson′s Disease, Shanghai 200025, China
Chen Haibo
Department of Neurology, Beijing Hospital, National Center of Gerontology, Beijing 100730, China
·
DOI： 10.3760/cma.j.cn113694-20200331-00233
0
0
0
0
0
0
PDF下载
APP内阅读
摘要

帕金森病是一种常见的中老年神经系统退行性疾病，近年来，我国学者无论是对帕金森病发病机制的认识，对早期诊断生物标志物的发现，还是对治疗理念的更新以及治疗方法和手段的探索，都有了显著的进步。中华医学会神经病学分会帕金森病及运动障碍学组于2006、2009年和2014年制定了第一、二、三版中国帕金森病治疗指南。6年来，国内外在该治疗领域又有了一些治疗理念的更新和治疗方法的进步。为了更好地适应其发展，指导临床实践，本文对6年前制定的第三版治疗指南进行了必要的修改和更新。

帕金森病;治疗学;指南
ABSTRACT

Parkinson′s disease is a common neurodegenerative disease in middle-aged and elderly people. In recent years, Chinese scholars have made significant progress in the understanding of the pathogenesis of Parkinson′s disease, the discovery of biomarkers for early diagnosis, as well as the renewal of therapeutic strategy. In 2006, 2009 and 2014, Chinese Society of Parkinson′s Disease and Movement Disorders developed the first, second and third edition of the Chinese Parkinson′s disease treatment guidelines. In the past six years, there have been some new progresses in therapeutic strategies. In order to better adapt to the development and guide clinical practice, this article have updated the recently developed therapeutic strategy based on the third edition of treatment guideline.

Parkinson disease;Therapeutics;Guideline
Chen Shengdi, Department of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Treatment and Research Center of Parkinson′s Disease, Shanghai 200025, China, Email: nc.defmoabc.hjrdsnehc
Chen Haibo, Department of Neurology, Beijing Hospital, National Center of Gerontology, Beijing 100730, China, Email: tendef.3ab62oruenbhnehc

None declared

Copyright by Chinese Medical Association
No content published by the journals of Chinese Medical Association may be reproduced or abridged without authorization. Please do not use or copy the layout and design of the journals without permission.
All articles published represent the opinions of the authors, and do not reflect the official policy of the Chinese Medical Association or the Editorial Board, unless this is clearly specified.
引用本文

中华医学会神经病学分会帕金森病及运动障碍学组,中国医师协会神经内科医师分会帕金森病及运动障碍学组. 中国帕金森病治疗指南（第四版）[J]. 中华神经科杂志,2020,53(12)：973-986.

DOI:10.3760/cma.j.cn113694-20200331-00233

PERMISSIONS

Request permissions for this article from CCC.

评价本文
*以上评分为匿名评价

版权归中华医学会所有。

未经授权，不得转载、摘编本刊文章，不得使用本刊的版式设计。

除非特别声明，本刊刊出的所有文章不代表中华医学会和本刊编委会的观点。

帕金森病（Parkinson′s disease）是一种常见的中老年神经系统退行性疾病，主要以黑质多巴胺能神经元进行性退变和路易小体形成的病理变化，纹状体区多巴胺递质降低、多巴胺与乙酰胆碱递质失平衡的生化改变，震颤、肌强直、动作迟缓、姿势平衡障碍的运动症状和睡眠障碍、嗅觉障碍、自主神经功能障碍、认知和精神障碍等非运动症状的临床表现为显著特征。流行病学调查研究显示欧美国家60岁以上帕金森病患病率达到1%，80岁以上超过4% ［ 1 ］ ，我国65岁以上人群患病率为1.7%，与欧美国家相似 ［ 2 ］ 。我国是世界上人口最多的国家，未来我国帕金森病患病人数将从2005年的199万人上升到2030年的500万人，几乎占到全球帕金森病患病人数的一半 ［ 3 ］ 。随着疾病的进展，帕金森病的运动和非运动症状会逐渐加重，一方面会损害患者本身的日常活动，另一方面，也会带来巨大的社会和医疗负担。
近年来，我国学者无论是对帕金森病发病机制的认识，对早期诊断生物标志物的发现，还是对治疗理念的更新以及治疗方法和手段的探索，都有了显著的进步。同时国外尤其是欧美国家的治疗指南给了我们很好的启示和借鉴。中华医学会神经病学分会帕金森病及运动障碍学组分别于2006、2009年和2014年制定了第一、二、三版中国帕金森病治疗指南 ［ 4 , 5 , 6 ］ ，对规范和优化我国帕金森病的治疗行为和提高治疗效果均起到了重要的作用 ［ 7 ］ 。近6年来，无论国外还是国内在该治疗领域都有治疗理念的更新和治疗方法的进步。为了更好地适应其发展，更好地指导临床实践，我们对6年前制定的第三版治疗指南进行必要的修改和更新。
试读结束，您可以通过登录机构账户或个人账户后获取全文阅读权限。
参考文献
1
Samii A , Nutt JG , Ransom BR . Parkinson′s disease[J]. Lancet, 2004,363(9423):1783-1793. DOI: 10.1016/S0140-6736(04)16305-8 .
返回引文位置Google Scholar
百度学术
万方数据
2
Zhang ZX , Roman GC , Hong Z ,et al. Parkinson′s disease in China: prevalence in Beijing, Xian, and Shanghai[J]. Lancet, 2005,365(9459):595-597. DOI: 10.1016/S0140-6736(05)17909-4 .
返回引文位置Google Scholar
百度学术
万方数据
3
Li G , Ma J , Cui S ,et al. Parkinson′s disease in China: a forty-year growing track of bedside work[J]. Transl Neurodegener, 2019,8:22. DOI: 10.1186/s40035-019-0162-z .
返回引文位置Google Scholar
百度学术
万方数据
4
中华医学会神经病学分会运动障碍及帕金森病学组. 帕金森病治疗指南[J]. 中华神经科杂志, 2006,39(6):409-412. DOI: 10.3760/j.issn:1006-7876.2006.06.025 .
返回引文位置Google Scholar
百度学术
万方数据
Chinese Society of Movement Disorders and Parkinson′s Disease. Guidelines for treatment of Parkinson′s disease[J]. Chin J Neurol, 2006,39(6):409-412. DOI: 10.3760/j.issn:1006-7876.2006.06.025 .
Goto CitationGoogle Scholar
Baidu Scholar
Wanfang Data
5
中华医学会神经病学分会帕金森病及运动障碍学组. 中国帕金森病治疗指南(第二版)[J]. 中华神经科杂志, 2009,42(5):352-355. DOI: 10.3760/cma.j.issn.1006-7876.2009.05.020 .
返回引文位置Google Scholar
百度学术
万方数据
Chinese Society of Parkinson′s Disease and Movement Disorders. Chinese guidelines for the treatment of Parkinson′s disease (second edition)[J]. Chin J Neurol, 2009,42(5):352-355. DOI: 10.3760/cma.j.issn.1006-7876.2009.05.020 .
Goto CitationGoogle Scholar
Baidu Scholar
Wanfang Data
6
中华医学会神经病学分会帕金森病及运动障碍学组. 中国帕金森病治疗指南(第三版)[J]. 中华神经科杂志, 2014,47(6):428-433. DOI: 10.3760/cma.j.issn.1006-7876.2014.06.017 .
返回引文位置Google Scholar
百度学术
万方数据
Chinese Society of Parkinson′s Disease and Movement Disorders. Chinese guidelines for the treatment of Parkinson′s disease (third edition)[J]. Chin J Neurol, 2014,47(6):428-433. DOI: 10.3760/cma.j.issn.1006-7876.2014.06.017 .
Goto CitationGoogle Scholar
Baidu Scholar
Wanfang Data
7
南海天,陈海波,李淑华,等. 帕金森病治疗指南对临床用药的影响[J]. 中华老年医学杂志, 2014,33(9):937-940. DOI: 10.3760/cma.j.issn.0254-9026.2014.09.003 .
返回引文位置Google Scholar
百度学术
万方数据
Nan HT , Chen HB , Li SH ,et al. Effect of Parkinson′s disease treatment guideline on medicine treatment[J]. Chin J Geriatr, 2014,33(9):937-940. DOI: 10.3760/cma.j.issn.0254-9026.2014.09.003 .
Goto CitationGoogle Scholar
Baidu Scholar
Wanfang Data
8
Santos-García D , de la Fuente-Fernández R . Impact of non-motor symptoms on health-related and perceived quality of life in Parkinson′s disease[J]. J Neurol Sci, 2013,332(1-2):136-140. DOI: 10.1016/j.jns.2013.07.005 .
返回引文位置Google Scholar
百度学术
万方数据
9
Radder DLM , de Vries NM , Riksen NP ,et al. Multidisciplinary care for people with Parkinson′s disease: the new kids on the block![J]. Expert Rev Neurother, 2019,19(2):145-157. DOI: 10.1080/14737175.2019.1561285 .
返回引文位置Google Scholar
百度学术
万方数据
10
Chen W , Xiao Q , Shao M ,et al. Prevalence of wearing-off and dyskinesia among the patients with Parkinson′s disease on levodopa therapy: a multi-center registry survey in mainland China[J]. Transl Neurodegener, 2014,3(1):26. DOI: 10.1186/2047-9158-3-26 .
返回引文位置Google Scholar
百度学术
万方数据
11
Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson′s disease[J]. N Engl J Med, 1993,328(3):176-183. DOI: 10.1056/NEJM199301213280305 .
返回引文位置Google Scholar
百度学术
万方数据
12
Olanow CW , Rascol O , Hauser R ,et al. A double-blind, delayed-start trial of rasagiline in Parkinson′s disease[J]. N Engl J Med, 2009,361(13):1268-1278. DOI: 10.1056/NEJMoa0809335 .
返回引文位置Google Scholar
百度学术
万方数据
13
Fox SH , Katzenschlager R , Lim SY ,et al. International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson′s disease[J]. Mov Disord, 2018,33(8):1248-1266. DOI: 10.1002/mds.27372 .
返回引文位置Google Scholar
百度学术
万方数据
14
Whone AL , Watts RL , Stoessl AJ ,et al. Slower progression of Parkinson′s disease with ropinirole versus levodopa: The REAL-PET study[J]. Ann Neurol, 2003,54(1):93-101. DOI: 10.1002/ana.10609 .
返回引文位置Google Scholar
百度学术
万方数据
15
Titova N , Chaudhuri KR . Personalized medicine in Parkinson′s disease: time to be precise[J]. Mov Disord, 2017,32(8):1147-1154. DOI: 10.1002/mds.27027 .
返回引文位置Google Scholar
百度学术
万方数据
16
National Institute for Health and Care Excellence. National Institute for Health and Care Excellence: clinical guidelines. Parkinson′s disease in adults: diagnosis and management[S]. London:National Institute for Health and Care Excellence, 2017.
返回引文位置
17
Poewe W , Antonini A , Zijlmans JC ,et al. Levodopa in the treatment of Parkinson′s disease: an old drug still going strong[J]. Clin Interv Aging, 2010,5:229-238. DOI: 10.2147/cia.s6456 .
返回引文位置Google Scholar
百度学术
万方数据
18
Warren Olanow C , Kieburtz K , Rascol O ,et al. Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson′s disease[J]. Mov Disord, 2013,28(8):1064-1071. DOI: 10.1002/mds.25364 .
返回引文位置Google Scholar
百度学术
万方数据
19
Liu G , Chen H , Su D ,et al. Risk thresholds of levodopa dose for dyskinesia in Chinese patients with Parkinson′s disease: a pilot study[J]. Neurol Sci, 2020,41(1):111-118. DOI: 10.1007/s10072-019-04043-7 .
返回引文位置Google Scholar
百度学术
万方数据
20
Cilia R , Akpalu A , Sarfo FS ,et al. The modern pre-levodopa era of Parkinson′s disease: insights into motor complications from sub-Saharan Africa[J]. Brain, 2014,137(Pt10):2731-2742. DOI: 10.1093/brain/awu195 .
返回引文位置Google Scholar
百度学术
万方数据
21
Bressman S , Saunders-Pullman R . When to start levodopa therapy for Parkinson′s disease[J]. N Engl J Med, 2019,380(4):389-390. DOI: 10.1056/NEJMe1814611 .
返回引文位置Google Scholar
百度学术
万方数据
22
Rascol O , Brooks DJ , Korczyn AD ,et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson′s disease who were treated with ropinirole or levodopa[J]. N Engl J Med, 2000,342(20):1484-1491. DOI: 10.1056/NEJM200005183422004 .
返回引文位置Google Scholar
百度学术
万方数据
23
Holloway RG , Shoulson I , Fahn S ,et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial [J]. Arch Neurol, 2004,61(7):1044-1053. DOI: 10.1001/archneur.61.7.1044 .
返回引文位置Google Scholar
百度学术
万方数据
24
Okun MS . Management of Parkinson disease in 2017: personalized approaches for patient-specific needs[J]. JAMA, 2017,318(9):791-792. DOI: 10.1001/jama.2017.7914 .
返回引文位置Google Scholar
百度学术
万方数据
25
Tomlinson CL , Stowe R , Patel S ,et al. Systematic review of levodopa dose equivalency reporting in Parkinson′s disease[J]. Mov Disord, 2010,25(15):2649-2653. DOI: 10.1002/mds.23429 .
返回引文位置Google Scholar
百度学术
万方数据
26
Connolly BS , Lang AE . Pharmacological treatment of Parkinson disease: a review[J]. JAMA, 2014,311(16):1670-1683. DOI: 10.1001/jama.2014.3654 .
返回引文位置Google Scholar
百度学术
万方数据
27
Olanow CW , Stocchi F . COMT inhibitors in Parkinson′s disease: can they prevent and/or reverse levodopa- induced motor complications?[J]. Neurology, 2004,62(1Suppl 1):S72-81. DOI: 10.1212/wnl.62.1_suppl_1.s72 .
返回引文位置Google Scholar
百度学术
万方数据
28
Antonini A , Moro E , Godeiro C ,et al. Medical and surgical management of advanced Parkinson′s disease[J]. Mov Disord, 2018,33(6):900-908. DOI: 10.1002/mds.27340 .
返回引文位置Google Scholar
百度学术
万方数据
29
张振馨,李辉,罗毅,等. 恩他卡朋治疗帕金森病的多中心、随机、双盲、安慰剂对照临床研究[J]. 中华神经科杂志, 2003,36(6):406-410. DOI: 10.3760/j.issn.1006-7876.2003.06.003 .
返回引文位置Google Scholar
百度学术
万方数据
Zhang ZX , Li H , Luo Y ,et al. A multiple center, randomized, double-blind, placebocontrolled clinical trial of entacapone in Parkinson′s disease patients with motor fluctuation[J]. Chin J Neurol, 2003,36(6):406-410. DOI: 10.3760/j.issn.1006-7876.2003.06.003 .
Goto CitationGoogle Scholar
Baidu Scholar
Wanfang Data
30
Armstrong MJ , Okun MS . Diagnosis and treatment of parkinson disease: a review[J]. JAMA, 2020,323(6):548-560. DOI: 10.1001/jama.2019.22360 .
返回引文位置Google Scholar
百度学术
万方数据
31
Poewe W , Seppi K , Tanner CM ,et al. Parkinson disease[J]. Nat Rev Dis Primers, 2017,3:17013. DOI: 10.1038/nrdp.2017.13 .
返回引文位置Google Scholar
百度学术
万方数据
32
Debu B , De Oliveira Godeiro C , Lino JC ,et al. Managing gait, balance, and posture in Parkinson′s disease[J]. Curr Neurol Neurosci Rep, 2018,18(5):23. DOI: 10.1007/s11910-018-0828-4 .
返回引文位置Google Scholar
百度学术
万方数据
33
Stocchi F , Olanow CW . Continuous dopaminergic stimulation in early and advanced Parkinson′s disease[J]. Neurology, 2004,62(1Suppl 1):S56-63. DOI: 10.1212/wnl.62.1_suppl_1.s56 .
返回引文位置Google Scholar
百度学术
万方数据
34
Ferreira JJ , Katzenschlager R , Bloem BR ,et al. Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson′s disease[J]. Eur J Neurol, 2013,20(1):5-15. DOI: 10.1111/j.1468-1331.2012.03866.x .
返回引文位置Google Scholar
百度学术
万方数据
35
Pahwa R , Factor SA , Lyons KE ,et al. Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology[J]. Neurology, 2006,66(7):983-995. DOI: 10.1212/01.wnl.0000215250.82576.87 .
返回引文位置Google Scholar
百度学术
万方数据
36
National Collaborating Centre for Chronic Conditions. Parkinson′s disease: national clinical guideline for diagnosis and management in primary and secondary care[S]. London:Royal College of Physicians, 2006.
返回引文位置
37
Cabreira V , Soares-da-Silva P , Massano J . Contemporary options for the management of motor complications in Parkinson′s disease: updated clinical review[J]. Drugs, 2019,79(6):593-608. DOI: 10.1007/s40265-019-01098-w .
返回引文位置Google Scholar
百度学术
万方数据
38
Stocchi F , Giorgi L , Hunter B ,et al. PREPARED: comparison of prolonged and immediate release ropinirole in advanced Parkinson′s disease[J]. Mov Disord, 2011,26(7):1259-1265. DOI: 10.1002/mds.23498 .
返回引文位置Google Scholar
百度学术
万方数据
39
Fabbri M , Rosa MM , Ferreira JJ . Adjunctive therapies in Parkinson′s disease: how to choose the best treatment strategy approach[J]. Drugs Aging, 2018,35(12):1041-1054. DOI: 10.1007/s40266-018-0599-2 .
返回引文位置Google Scholar
百度学术
万方数据
40
Pilleri M , Antonini A . Therapeutic strategies to prevent and manage dyskinesias in Parkinson′s disease[J]. Expert Opin Drug Saf, 2015,14(2):281-294. DOI: 10.1517/14740338.2015.988137 .
返回引文位置Google Scholar
百度学术
万方数据
41
Seppi K , Ray Chaudhuri K , Coelho M ,et al. Update on treatments for nonmotor symptoms of Parkinson′s disease-an evidence-based medicine review[J]. Mov Disord, 2019,34(2):180-198. DOI: 10.1002/mds.27602 .
返回引文位置Google Scholar
百度学术
万方数据
42
Liu CF , Wang T , Zhan SQ ,et al. Management recommendations on sleep disturbance of patients with Parkinson′s disease[J]. Chin Med J, 2018,131(24):2976-2985. DOI: 10.4103/0366-6999.247210 .
返回引文位置Google Scholar
百度学术
万方数据
43
Barone P , Amboni M , Vitale C ,et al. Treatment of nocturnal disturbances and excessive daytime sleepiness in Parkinson′s disease[J]. Neurology, 2004,63(8Suppl 3):S35-38. DOI: 10.1212/wnl.63.8_suppl_3.s35 .
返回引文位置Google Scholar
百度学术
万方数据
44
Torti M , Bravi D , Vacca L ,et al. Are all dopamine agonists essentially the same?[J]. Drugs, 2019,79(7):693-703. DOI: 10.1007/s40265-019-01103-2 .
返回引文位置Google Scholar
百度学术
万方数据
45
Winkelmann J , Allen RP , Högl B ,et al. Treatment of restless legs syndrome: Evidence-based review and implications for clinical practice (Revised 2017) § [J]. Mov Disord, 2018,33(7):1077-1091. DOI: 10.1002/mds.27260 .
返回引文位置Google Scholar
百度学术
万方数据
46
Jost WH , Buhmann C . The challenge of pain in the pharmacological management of Parkinson′s disease[J]. Expert Opin Pharmacother, 2019,20(15):1847-1854. DOI: 10.1080/14656566.2019.1639672 .
返回引文位置Google Scholar
百度学术
万方数据
47
Rukavina K , Leta V , Sportelli C ,et al. Pain in Parkinson′s disease: new concepts in pathogenesis and treatment[J]. Cur Opin Neurol, 2019,32(4):579-588. DOI: 10.1097/WCO.0000000000000711 .
返回引文位置Google Scholar
百度学术
万方数据
48
Schneider RB , Iourinets J , Richard IH . Parkinson′s disease psychosis: presentation, diagnosis and management[J]. Neurodegener Dis Manag, 2017,7(6):365-376. DOI: 10.2217/nmt-2017-0028 .
返回引文位置Google Scholar
百度学术
万方数据
49
Goodarzi Z , Mrklas KJ , Roberts DJ ,et al. Detecting depression in Parkinson disease: a systematic review and meta-analysis[J]. Neurology, 2016,87(4):426-437. DOI: 10.1212/WNL.0000000000002898 .
返回引文位置Google Scholar
百度学术
万方数据
50
Broen MP , Narayen NE , Kuijf ML ,et al. Prevalence of anxiety in Parkinson′s disease: a systematic review and meta-analysis[J]. Mov Dis, 2016,31(8):1125-1133. DOI: 10.1002/mds.26643 .
返回引文位置Google Scholar
百度学术
万方数据
51
Lizarraga KJ , Fox SH , Strafella AP ,et al. Hallucinations, delusions and impulse control disorders in Parkinson disease[J]. Clin Geriatr Med, 2020,36(1):105-118. DOI: 10.1016/j.cger.2019.09.004 .
返回引文位置Google Scholar
百度学术
万方数据
52
Weintraub D , David AS , Evans AH ,et al. Clinical spectrum of impulse control disorders in Parkinson′s disease[J]. Mov Disord, 2015,30(2):121-127. DOI: 10.1002/mds.26016 .
返回引文位置Google Scholar
百度学术
万方数据
53
Weintraub D , Mamikonyan E . Impulse control disorders in Parkinson′s disease[J]. Am J Psychiatry, 2019,176(1):5-11. DOI: 10.1176/appi.ajp.2018.18040465 .
返回引文位置Google Scholar
百度学术
万方数据
54
Vargas AP , Cardoso FEC . Impulse control and related disorders in Parkinson′s disease[J]. Arq Neuropsiquiatr, 2018,76(6):399-410. DOI: 10.1590/0004-282X20180052 .
返回引文位置Google Scholar
百度学术
万方数据
55
Aarsland D , Creese B , Politis M ,et al. Cognitive decline in Parkinson disease[J]. Nat Rev Neurol, 2017,13(4):217-231. DOI: 10.1038/nrneurol.2017.27 .
返回引文位置Google Scholar
百度学术
万方数据
56
中国帕金森病脑深部刺激疗法专家组. 中国帕金森病脑深部刺激疗法专家共识[J]. 中华神经科杂志, 2012,45(7):541-543. DOI: 10.3760/cma.j.issn.1006-7876.2012.07.023 .
返回引文位置Google Scholar
百度学术
万方数据
Chinese Expert Group on Deep Brain Stimulation Therapy for Parkinson′s Disease. Consensus of Chinese experts on deep brain stimulation therapy for Parkinson′s Disease[J]. Chin J Neurol, 2012,45(7):541-543. DOI: 10.3760/cma.j.issn.1006-7876.2012.07.023 .
Goto CitationGoogle Scholar
Baidu Scholar
Wanfang Data
57
中华医学会神经外科学分会功能神经外科学组,中华医学会神经病学分会帕金森病及运动障碍学组,中国医师协会神经内科医师分会帕金森病及运动障碍学组,等. 中国帕金森病脑深部电刺激疗法专家共识(第二版)[J]. 中华神经外科杂志, 2020,36(4):325-337. DOI: 10.3760/cma.j.cn112050-20200217-00062 .
返回引文位置Google Scholar
百度学术
万方数据
Chinese Society of Functional Neurosurgery,Chinese Society of Parkinson′s Disease and Movement Disorders,Parkinson′s disease and Movement Disorder Section of Neurology branch of Chinese Medical Doctor Association,et al. Expert consensus on deep brain stimulation therapy for Parkinson′s disease in China (second edition)[J]. Chin J Neurosurg, 2020,36(4):325-337. DOI: 10.3760/cma.j.cn112050-20200217-00062 .
Goto CitationGoogle Scholar
Baidu Scholar
Wanfang Data
58
Bloem BR , de Vries NM , Ebersbach G . Non- pharmacological treatments for patients with Parkinson′s disease[J]. Mov Disord, 2015,30(11):1504-1520. DOI: 10.1002/mds.26363 .
返回引文位置Google Scholar
百度学术
万方数据
59
Koychev I , Okai D . Cognitive-behavioural therapy for non-motor symptoms of Parkinson′s disease: a clinical review[J]. Evid Based Ment Health, 2017,20(1):15-20. DOI: 10.1136/eb-2016-102574 .
返回引文位置Google Scholar
百度学术
万方数据
60
Morgenthaler T , Kramer M , Alessi C ,et al. Practice parameters for the psychological and behavioral treatment of insomnia: an update. An American Academy of Sleep Medicine Report[J]. Sleep, 2006,29(11):1415-1419.
返回引文位置Google Scholar
百度学术
万方数据
61
Vacca VM . Parkinson disease: enhance nursing knowledge[J]. Nursing, 2019,49(11):24-32. DOI: 10.1097/01.NURSE.0000585896.59743.21 .
返回引文位置Google Scholar
百度学术
万方数据
62
Zhan A , Mohan S , Tarolli C ,et al. Using smartphones and machine learning to quantify Parkinson disease severity: the Mobile Parkinson Disease Score[J]. JAMA Neurol, 2018,75(7):876-880. DOI: 10.1001/jamaneurol.2018.0809 .
返回引文位置Google Scholar
百度学术
万方数据
63
Ekker MS , Janssen S , Nonnekes J ,et al. Neurorehabilitation for Parkinson′s disease: future perspectives for behavioural adaptation[J]. Parkinsonism Relat Disord, 2016,22Suppl 1:S73-77. DOI: 10.1016/j.parkreldis.2015.08.031 .
返回引文位置Google Scholar
百度学术
万方数据
64
Schneider RB , Biglan KM . The promise of telemedicine for chronic neurological disorders: the example of Parkinson′s disease[J]. Lancet Neurol, 2017,16(7):541-551. DOI: 10.1016/S1474-4422(17)30167-9 .
返回引文位置Google Scholar
百度学术
万方数据
备注信息
A
陈生弟，上海交通大学医学院附属瑞金医院神经内科，帕金森病诊疗研究中心200025，Email： nc.defmoabc.hjrdsnehc
B
陈海波，北京医院神经内科，国家老年医学中心100730，Email： tendef.3ab62oruenbhnehc
C

中华医学会神经病学分会帕金森病及运动障碍学组, 中国医师协会神经内科医师分会帕金森病及运动障碍学组. 中国帕金森病治疗指南（第四版）[J]. 中华神经科杂志, 2020, 53(12): 973-986. DOI: 10.3760/cma.j.cn113694-20200331-00233.

D
所有作者均声明不存在利益冲突
E
None declared
评论 （0条）
注册
登录
时间排序
暂无评论，发表第一条评论抢沙发
MedAI助手（体验版）
文档即答
智问智答
机器翻译
回答内容由人工智能生成，我社无法保证其准确性和完整性，该生成内容不代表我们的态度或观点，仅供参考。
生成快照
文献快照

你好，我可以帮助您更好的了解本文，请向我提问您关注的问题。

0/2000

《中华医学会杂志社用户协议》 | 《隐私政策》

《SparkDesk 用户协议》 | 《SparkDesk 隐私政策》

网信算备340104764864601230055号 | 网信算备340104726288401230013号

技术支持：

历史对话
本文全部
还没有聊天记录
设置
模式
纯净模式沉浸模式
字号
小中大